Verona Pharma plc (VRNA) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 London, 영국. 현재 CEO는 David S. Zaccardelli.
VRNA 을(를) 보유 IPO 날짜 2017-04-28, 209 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $72.68B.
Verona Pharma plc is a clinical-stage biopharmaceutical company headquartered in London, focused on developing innovative therapies for respiratory diseases with significant unmet medical needs. The company's lead product candidate is ensifentrine, an inhaled dual inhibitor of phosphodiesterase 3 and 4 enzymes that functions as both a bronchodilator and anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis, with development proceeding across three delivery formulations: nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Founded in 2005, Verona Pharma is advancing a potentially transformative approach to respiratory disease management.
